A Phase IB Study of Belvarafenib Alone and in Combination with Cobimetinib in People with Advanced Melanoma Who Had Immunotherapy
Source: Memorial Sloan Kettering Cancer Centre
The purpose of this study is to find the highest dose of the investigational drug belvarafenib that can be given safely alone and with cobimetinib in people with advanced NRAS-mutated melanoma that continues to grow despite prior treatment with immunotherapy. In earlier studies, belvarafenib was shown to stop the growth of cancer cells in advanced NRAS-mutant melanoma.
